Attovia Therapeutics (NASDAQ:ATTO) Stock Price Target Raised at Morgan Stanley

Posted by Francis Steltz on Nov 10th, 2026

Attovia Therapeutics (NASDAQ:ATTO – Get Free Report) had its price objective lifted by equities researchers at Morgan Stanley from $39.00 to $40.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley‘s target price would suggest a potential upside of 144.65% from the stock’s previous close.

A number of other equities analysts also recently weighed in on ATTO. Leerink Partners began coverage on shares of Attovia Therapeutics in a report on Monday, August 31st. They issued an “outperform” rating and a $52.00 price target on the stock. Zacks Research upgraded Attovia Therapeutics to a “hold” rating in a research report on Friday, September 4th. Citigroup initiated coverage on shares of Attovia Therapeutics in a report on Monday, August 31st. They issued a “buy” rating and a $30.00 price target on the stock. Royal Bank Of Canada assumed coverage on shares of Attovia Therapeutics in a report on Monday, August 31st. They issued an “outperform” rating and a $45.00 price objective for the company. Finally, Lifesci Capital initiated coverage on shares of Attovia Therapeutics in a report on Monday, August 31st. They set an “outperform” rating and a $45.00 price target for the company. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Attovia Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $42.40.

Get Our Latest Report on Attovia Therapeutics

Attovia Therapeutics Trading Up 2.4%

Shares of NASDAQ ATTO traded up $0.39 during midday trading on Tuesday, hitting $16.35. 37,507 shares of the stock traded hands, compared to its average volume of 345,904. Attovia Therapeutics has a one year low of $12.94 and a one year high of $28.00. The company’s 50 day moving average is $18.06. The company has a market capitalization of $746.38 million and a P/E ratio of -3.34.

Attovia Therapeutics (NASDAQ:ATTO – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02). The company’s revenue for the quarter was down 100.0% compared to the same quarter last year. During the same quarter last year, the business posted ($3.44) earnings per share. Research analysts predict that Attovia Therapeutics will post -4.06 earnings per share for the current fiscal year.